Aerie completes enrollment in mid-stage netarsudil study in Japan

Several months ahead of schedule, Aerie Pharmaceuticals (NASDAQ:AERI) has completed the enrollment of 215 open-angle glaucoma/ocular hypertension patients in a Phase 2 clinical trial in Japan evaluating netarsudil ophthalmic solution 0.02% (branded as Rhopressa in the U.S.) in this population. Topline results should be available in Q4.

If successful, Phase 3 studies will follow.

https://seekingalpha.com/news/3476400-aerie-pharma-completes-enrollment-mid-stage-netarsudil-study-japan